Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

Oxurion misses in macular edema trial
Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317 plus Lucentis ranibizumab did not improve

Read the full 233 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE